{
    "clinical_study": {
        "@rank": "1576", 
        "brief_summary": {
            "textblock": "The study is to identify the effectiveness of Eprosartan on pulse pressure in hypertensive\n      patients with metabolic syndrome\n\n      -Definition of pulse pressure (PP): Difference between systolic and diastolic blood pressure\n      produced one heart beat."
        }, 
        "brief_title": "Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "Primary Objective\n\n      -To assess the changes of pulse pressure at 12 weeks\n\n      Secondary Objectives\n\n        -  To assess the changes of pulse pressure at 4, 24 weeks\n\n        -  To assess the changes of systolic blood pressure and diastolic blood pressure at each\n           visit\n\n        -  Percentage of responder rate* at each visit and time to get normalized BP from\n           enrollment\n\n        -  Responder rate at last visit\n\n        -  To assess IIEF-5 (5-item Version of the International Index of Erectile Function) score\n           at enrollment and 24 weeks (percentage of patients with ED according to IIEF-5, Changes\n           of IIEF-5 domains)\n\n        -  Percentage of patients with erectile dysfunction (ED) according to IIEF-5 and changes\n           of PP in subgroup (age 65, body mass index (BMI) 23, diabetes mellitus, dyslipidemia,\n           benign prostate hypertrophy)\n\n        -  Analysis of correlation between ED and concomitant disease and concomitant medications\n           in patients who received Eprosartan\n\n        -  Score changes of Framingham 10-year Coronary Heart Disease (CHD) risk at 1st visit, 4th\n           visit\n\n        -  Percentages of Eprosartan monotherapy and multiple antihypertensive therapies at\n           enrollment and last visit\n\n        -  Reason for treatment discontinuation (Inadequate BP control, adverse events, others)\n\n        -  Adverse events\n\n             -  Responder rate: SBP <140mmHg and DBP <90mmHg (SBP <140mmHg and DBP <85mmHg for\n                patients with diabetes mellitus)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 40-80 years old male  patient at the 1st visit\n\n          2. Patient who is determined to prescribe Eprosartan for hypertension (patient with at\n             least one of the following conditions) (1) Newly diagnosed hypertension (2) Inability\n             to tolerate hypertension (for example: adverse event) (3) Lack of response to current\n             antihypertensive medications\n\n          3. Metabolic syndrome patient (3 or more of below components within 3 months before\n             enrollment) (1) Waist circumference (>90 for men) (2) Triglycerides (\u2265150mg/dl) (3)\n             HDL cholesterol (<40mg/dl for men) (4) SBP\u2265130mmHg or DBP\u226585mmHg or on\n             antihypertensive medications) (5) Fasting glucose level (\u2265100mg/dl) or on\n             antidiabetic medications\n\n               -  MS diagnosis origin: Korean diabetes association\n\n        Exclusion Criteria:\n\n          1. Patients who is administered with 3 or more than 3 antihypertensive drugs\n\n          2. Patients who is contraindicated with Eprosartan by the product label"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "General hospitals"
            }
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02024100", 
            "org_study_id": "HD_EPR_OS2013"
        }, 
        "intervention_browse": {
            "mesh_term": "Eprosartan"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "contact": {
                "last_name": "Chang Hwan Yoon, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Seongnam-si", 
                    "country": "Korea, Republic of", 
                    "state": "Bundang-gu", 
                    "zip": "463-717"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }, 
            "investigator": {
                "last_name": "Chang Hwan Yoon, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure in Hypertensive Patients With Metabolic Syndrome", 
        "overall_contact": {
            "email": "dongjin.shin@handok.com", 
            "last_name": "Dongjin Shin", 
            "phone": "82-2-527-5383"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Bundang Hospital", 
            "last_name": "Chang Hwan Yoon, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Calculating pulse pressure at 3rd(12weeks) visit and it will be presented in descriptive statistics quantity", 
            "measure": "To assess the changes of pulse pressure at 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02024100"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Calculating pulse pressure at each visit and it will be presented in descriptive statistics quantity\nVariation of the pulse pressure at each visit will be presented in descriptive statistics quantity and average variation's 95% confidence interval will be calculated\nCalculating systolic blood pressure and diastolic blood pressure at each visit and it will be presented in descriptive statistics quantity\nSeverity of erectile dysfunction will be presented a contingency table and symmetry testing will be done whether there is a significant difference in the data\nAs sub-analysis, type of study drug, age, BMI, with/without diabetes mellitus, with/without dyslipidemia, with/without benign prostate hypertrophy, type of treatment will be considered\nFor safety analysis, overall incidence rate of adverse event will be presented and frequency and percentage will be presented according to body organs and preferable terminology", 
            "measure": "- changes of pulse pressure at 4, 24 weeks - changes of blood pressure at 4, 12, 24 weeks - Duration to get normalized BP - assess IIEF-5 score - Score changes of Framingham 10-year CHD risk", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "source": "Handok Pharmaceuticals Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Handok Pharmaceuticals Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}